Instem had expressions of interest from five other parties after the pharma services group agreed to a £203 million takeover from private equity group Archimed, it said today.
The five prospective bidders had access to management and financial information, it said, but all have now withdrawn their interest.
No discussions are ongoing with any of the potential offerors nor any other third party regarding a potential competing offer for Instem, the statement added.
Even so, Instem has adjourned the meeting scheduled for tomorrow to ratify the Archimed deal until 2 November to give shareholders additional time to consider how they will vote.